ROCKET PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financing Activities
During the six months ended June 30, 2026, financing activities provided $0.1 million of cash consisting of proceeds from issuance of common stock from the exercise of stock options, partially offset by pay down of finance lease obligations.
During the six months ended June 30, 2025, financing activities provided $0.2 million of cash, consisting of return of short-swing profits.
Contractual Obligations and Commitments
Information regarding contractual obligations and commitments may be found in Note 14 of our unaudited interim consolidated financial statements in this Quarterly Report on Form 10-Q. We do not have any off-balance sheet arrangements that are material or reasonably likely to become material to our financial condition or results of operations.
Recently Issued Accounting Pronouncements
There were no recent accounting pronouncements that impacted the Company, or which had a significant effect on the consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.